CTL Amedica to Enter Asian Market with Interbody Fusion Devices

CTL Amedica Valeo Implants

The Taiwan Food and Drug Administration granted CTL Amedica a license for the silicon nitride-based spinal platform of the Valeo II Lumbar Interbody Fusion Device, Valeo C+CSC Cervical Interbody Fusion Device and the Valeo II Cervical Interbody Fusion Device.

The product line is projected to launch in late 2020 in the region through...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us